Prothrombotic autoantibodies targeting platelet factor 4/polyanion are associated with pediatric cerebral malaria

Iset M Vera1, Anne Kessler2, Visopo Harawa3,4,5

  • 1Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, Tampa, Florida, USA.

Insights

Thrombogenic autoantibodies, specifically anti-platelet factor 4/polyanion (anti-PF4/P) IgG, are elevated in cerebral malaria (CM). These antibodies contribute to platelet activation and may drive thrombosis, a key complication in CM.

Area of Science:

  • * Immunology
  • * Hematology
  • * Infectious Diseases

Background:

  • * Cerebral malaria (CM) is characterized by consumptive coagulopathy and thromboinflammation.
  • * The role of thrombogenic autoantibodies in CM's procoagulant state requires investigation.

Purpose of the Study:

  • * To investigate the association between specific autoantibodies and the procoagulant state in pediatric CM.
  • * To determine if autoantibodies contribute to CM pathogenesis and clinical outcomes.

Main Methods:

  • * Plasma samples from children with uncomplicated malaria (UM), CM, nonmalarial coma (NMC), and healthy controls (HCs) were analyzed.
  • * Enzyme-linked immunosorbent assay (ELISA) was used to detect autoantibodies including anti-PF4/P and anti-phosphatidylserine (anti-PS).
  • * Associations with clinical and immune biomarkers were assessed using regression analyses.

Main Results:

  • * Elevated levels of anti-PF4/P IgG and anti-PS IgG were observed in malaria patients compared to HCs and NMC patients.
  • * Anti-PF4/P IgG levels were significantly higher in CM patients than in UM patients.
  • * In CM patients with retinopathy, anti-PF4/P IgG correlated with lower platelet counts and higher mortality, and induced greater ex vivo platelet activation.

Conclusions:

  • * Elevated anti-PF4/P autoantibodies are associated with CM.
  • * These autoantibodies may promote thrombosis and contribute to CM's severe clinical manifestations.
  • * Targeting anti-PF4/P autoantibodies could be a therapeutic strategy for CM.